Nanovibronix (NASDAQ:FEED) Stock Rating Upgraded by Wall Street Zen

Nanovibronix (NASDAQ:FEED) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Separately, Weiss Ratings assumed coverage on shares of Nanovibronix in a research report on Tuesday, January 27th. They set a “sell (e+)” rating on the stock. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Nanovibronix has an average rating of “Sell”.

Nanovibronix Price Performance

NASDAQ:FEED opened at $1.96 on Friday. Nanovibronix has a twelve month low of $0.99 and a twelve month high of $162.50. The firm has a market cap of $2.14 million, a price-to-earnings ratio of -0.05 and a beta of 2.09. The business’s 50 day moving average is $2.31.

Insider Buying and Selling

In related news, major shareholder Christian Michael Glibert purchased 240,000 shares of the stock in a transaction on Wednesday, January 14th. The shares were purchased at an average cost of $2.67 per share, with a total value of $640,800.00. Following the acquisition, the insider directly owned 240,000 shares in the company, valued at $640,800. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 1.40% of the company’s stock.

About Nanovibronix

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.